Tools
Stock profile

INCYTE CORP (INCY)

INCY · Latest close $117.80 as of Nov 18, 2026 · 13F data as of Jun 30, 2026 (2026 Q2)
Latest close
$117.80
As of Nov 18, 2026
Tracked funds holding
3 of 149
2026 Q2 13F filings
Opened / added
0 / 1
vs previous quarter
Trimmed / exited
2
vs previous quarter

INCYTE CORP (INCY) is held by 3 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 1 fund adding and 2 funds trimming or exiting versus the previous quarter. Insiders were net sellers over the last 90 days ($0 bought vs $33.3M sold). Latest close $117.80 as of Nov 18, 2026.

Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Nov 16, 2026 · Congress to Nov 16, 2026.

Funds
2026 Q2 13F
Insiders · 90d
net $-33.3M
Fundamentals
Revenue · FY2025
Red flags
none flagged
Short interest
as of Oct 15, 2026
Holdings · Charts · All institutions · Fundamentals · Short interest · Fails to deliver · Insider trading · 5% holders · Planned sales · Politician trading · Committee jurisdiction · Government relations · Screens & lenses · Signal record · Related stocks · Recent 8-K

Funds holding this

Baker Bros. Advisors · Sound Shore · Dodge & Cox Funds — 3 tracked funds hold INCY. See all holders.

Insider and Congress activity

Insiders bought on the open market (0 purchases, $0) vs 17 sales ($33.3M). Insider trading

Often held alongside

ICON PLC (ICLR) · IQVIA HOLDINGS INC. (IQV) · Medpace Holdings, Inc. (MEDP) · CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) · VSE CORP (VSEC) — stocks the same funds also hold. See all related stocks.

Super-investor holdings · 2026 Q2

FundPortfolio weightSharesChange vs prev. quarter
Baker Bros. Advisors17.48%30,762,330ADDED (+0.1%) Q3 filed Nov 16
Sound Shore2.64%757,723TRIMMED (-1.3%) Q3 filed Nov 6
Dodge & Cox Funds0.71%11,957,326TRIMMED (-2.4%) Q3 filed Nov 13

Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.

Price change since quarter-end: +4.6% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.

Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.

Charts

129.9352.182024-11-192026-11-18

Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.

All institutions · Form 13F

Institutions holding857 of 8,857 filers
Long-only filers among them852
Change vs 2026 Q1+57 net · 772 entered · 715 exited
Shares reported, all filers201,371,341
Reported value, all filers$21.8B

Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).

Company fundamentals

ExchangeNasdaq
IndustryServices-Commercial Physical & Biological Research (SIC 8731)
Revenue · FY2025$5.1B
Net income · FY2025$1.3B
Total assets · FY2025$7.0B
Shares outstanding203,832,492
Market cap (at latest close)$24.0B

Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Oct 22, 2026.

Short interest

Shares short · Oct 15, 202610,025,354
Share of shares outstanding4.92%
Days to cover5.32

Shares short at recent settlements — Jul 31, 2026: 10.2M · Aug 14, 2026: 9.4M · Aug 31, 2026: 9.4M · Sep 15, 2026: 10.0M · Sep 30, 2026: 10.0M · Oct 15, 2026: 10.0M.

Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Oct 22, 2026.

Fails to deliver

Shares failed to deliver · Oct 14, 20266
Share of shares outstanding0.00%
Fails as a share of short interest · Oct 15, 2026<0.1%

Fails to deliver at recent settlements — Jul 31, 2026: 12K · Aug 14, 2026: 0 · Aug 31, 2026: 7 · Sep 15, 2026: 0 · Sep 30, 2026: 0 · Oct 14, 2026: 6.

Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Oct 22, 2026.

Insider trading · Form 4

0 insiders bought on the open market in the last 90 days (0 purchases, $0), against 17 sales by 4 insiders ($33.3M).

Source: SEC Form 4 filings. Open-market transactions only.

Recent open-market trades

DateInsiderRoleBuy / SellSharesPriceValueSource
Nov 16, 2026Stein Steven HCMO & Head of Late-Stage Dev.Sell576$121.98$70.3KSEC filing
Nov 16, 2026CAGNONI PABLO JPresident, Global Head of R&DSell877$121.98$107.0KSEC filing
Nov 16, 2026CAGNONI PABLO JPresident, Global Head of R&DSell1,765$120.46$212.6KSEC filing
Nov 13, 2026Heeson LeeEVP, Head of Incyte IntlSell1,471$121.89$179.3KSEC filing
Nov 13, 2026Heeson LeeEVP, Head of Incyte IntlSell2,200$120.44$265.0KSEC filing
Nov 13, 2026Heeson LeeEVP, Head of Incyte IntlSell874$121.16$105.9KSEC filing
Nov 13, 2026Heeson LeeEVP, Head of Incyte IntlSell3,700$120.33$445.2KSEC filing
Nov 13, 2026Heeson LeeEVP, Head of Incyte IntlSell2,449$121.13$296.7KSEC filing
Nov 6, 2026Stein Steven HCMO & Head of Late-Stage Dev.Sell35,042$116.06$4.1MSEC filing
Nov 6, 2026Stein Steven HCMO & Head of Late-Stage Dev.Sell22,336$117.14$2.6MSEC filing

Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.

Planned sales · Form 144

FiledSellerRoleShares to sellMarket valueApprox. sale dateSource
Sep 15, 2026PABLO CAGNONIOfficer23,218$2.8MSep 15, 2026SEC filing
Aug 19, 2026PABLO CAGNONIOfficer10,801$1.4MAug 19, 2026SEC filing
Aug 12, 2026PABLO CAGNONIOfficer10,803$1.3MAug 12, 2026SEC filing
Aug 5, 2026PABLO CAGNONIOfficer10,640$1.3MAug 5, 2026SEC filing
Aug 5, 2026PATRICK A MAYESOfficer2,207$273.6KAug 5, 2026SEC filing
Aug 3, 2026PATRICK A MAYESOfficer6,055$729.2KAug 3, 2026SEC filing
Jul 31, 2026PATRICK A MAYESOfficer41,899$5.0MJul 31, 2026SEC filing
Jul 31, 2026PABLO CAGNONIOfficer15,888$1.9MJul 31, 2026SEC filing
Jul 16, 2026STEVEN STEINOfficer1,877$215.3KJul 16, 2026SEC filing
Jul 16, 2026MOHAMED ISSAOfficer1,093$125.7KJul 16, 2026SEC filing

A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.

Activist disclosure · Schedule 13D

FiledFormPrice change since disclosure
May 11, 2026SCHEDULE 13D/A+20.1% (close May 12, 2026 → Nov 17, 2026)

Reference close is the first trading day after the filing (May 12, 2026). A Schedule 13D reports beneficial ownership, not a purchase — there is no transaction price to show. Source: SEC EDGAR Schedule 13D filings.

5% holders · Schedule 13D/G

FiledFilerFormShares% ownedEvent dateSource
May 14, 2026Dodge & CoxSC 13G/A12,252,3566.2%Mar 31, 2026SEC filing
May 11, 2026Baker Bros. Advisors LPSC 13D/A30,865,07715.4%May 7, 2026SEC filing
Apr 30, 2026Vanguard Capital ManagementSC 13G12,591,6306.3%Mar 31, 2026SEC filing
Mar 27, 2026The Vanguard GroupSC 13G/A00.0%Mar 13, 2026SEC filing
Feb 10, 2026Baker Bros. Advisors LPSC 13D/A30,852,92215.5%Feb 6, 2026SEC filing
Nov 10, 2025STATE STREET CORPORATIONSC 13G9,677,4145.0%Sep 30, 2025SEC filing
Oct 17, 2025BlackRock, Inc.SC 13G/A15,242,1717.8%Sep 30, 2025SEC filing

One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.

Politician trading · U.S. Congress

Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).

Committee jurisdiction

Industry: Services-Commercial Physical & Biological Research (SIC 8731). No standing committee maps to this industry under the site’s jurisdiction rule — see Methodology.

Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.

Government relations

Lobbying: 129 Lobbying Disclosure Act filings named this company as client, 1999–2026; most common issues: Medicare/Medicaid (99), Health Issues (52), Copyright/Patent/Trademark (6).

Federal contracts: $452.4K in obligated amounts, fiscal years 2021–2026.

Fiscal yearObligated amount
FY2021$292.7K
FY2022$-63.6K
FY2023$102.2K
FY2024$121.1K
FY2025$0
FY2026$0

Largest awards collected

Award IDAgencyAmountStart
36C26124N0749Department of Veterans Affairs$119.6KJul 2, 2024
36C24121F0107Department of Veterans Affairs$63.6KJan 19, 2021
36C24122F0150Department of Veterans Affairs$25.5KApr 27, 2022
36C26124N0511Department of Veterans Affairs$13.3KMar 18, 2024
36C26124N0408Department of Veterans Affairs$13.3KJan 26, 2024

Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.

Screens & lenses

Financial Screens

· Growth — Revenue up every year for 5 straight years

· Graham — Sound finances and a long run of profits

· Greenblatt Magic Formula — High earnings yield and high return on capital together

· O'Neil CAN SLIM — Explosive earnings growth leaders

· Earnings Quality (Cash Conversion) — Profits that actually come back as cash

Chart Signals

· Monthly Uptrend — Price above its 12-month moving average

· Top Relative Strength — Top 20% of the universe by 6-month return

Key figures

· Growth — Latest revenue: $5.1B · 5-yr revenue CAGR: 14.0% · Straight growth years: 14

· Graham — Current ratio: 3.32 · Straight profitable years: 5 · Debt ratio: 0.35 · Latest net income: $1.3B

· Greenblatt Magic Formula — Earnings yield: 6.8% · Return on capital: 35.7% · Combined rank: 85

· O'Neil CAN SLIM — 3-yr EPS growth: 61.6% · ROE: 24.9% · Latest revenue growth: 21.2%

· Earnings Quality (Cash Conversion) — Cash conversion (3-yr avg): 4.07 · Operating cash flow: $1.4B · Net income: $1.3B

Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.

Also held by the tracked funds that hold INCY — ranked by lift, the co-holding pattern described in Methodology: ICON PLC (ICLR) · IQVIA HOLDINGS INC. (IQV) · Medpace Holdings, Inc. (MEDP) · CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) · VSE CORP (VSEC) · Genpact LTD (G) · PAYCHEX INC (PAYX) · Booz Allen Hamilton Holding Corp (BAH).

8 of the 8 are same-industry (SIC) fillers: fewer than 4 stocks met the lift rule for this stock.

Recent 8-K filings

FiledItemsSource
Nov 13, 20268.01 Other EventsSEC filing
Oct 29, 20262.02 Results of Operations and Financial Condition · 9.01 Financial Statements and ExhibitsSEC filing
Aug 31, 20268.01 Other EventsSEC filing

Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.

Related

ICON PLC (ICLR) · Track Record: how the signals scored · Practice timing on INCY

One email a week: the week’s new filings and research. Subscribe free

← INBX  ·  INDA →

Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.